Costi diretti e indiretti assorbiti dalle patologie HCV-indotte in Italia: stima basata su una metodologia probabilistica di Cost of Illness

Marcellusi, Andrea; Viti, Raffaella; Capone, Alessandro; Mennini, Francesco Saverio

doi:10.1007/s40276-014-0023-9

Cited by 14 publications

(29 citation statements)

References 24 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…L'arrivo dei biosimilari e l'effetto competitivo rispetto ai farmaci biologici hanno permesso, almeno in alcune aree terapeutiche, di garantire un risparmio per i Sistemi sanitari (23). L'analisi condotta da Marcellusi et al, lungo un orizzonte temporale di sei anni, ha stimato l'impatto finanziario aggregato dei biosimilari di infliximab ed etanercept nel trattamento dell'artrite reumatoide, della psoriasi, delle malattie infiammatorie intestinali e dell'artrite psoriasica (27). Grazie all'introduzione sul mercato di questi farmaci biologici si potrebbero risparmiare dai 132 ai 296 milioni di euro.…”

Section: Discussioneunclassified

Budget impact analysis of pegfilgrastim biosimilar in the treatment of febrile neutropenia in Italy

Ravasio¹,

Antonuzzo

Danova³

et al. 2020

abtpn

View full text Add to dashboard Cite

Introduction: Granulocyte-colony stimulating factors (G-CSFs) can significantly reduce the risk of febrile neutropenia (FN) among certain patients receiving chemotherapy. FN is associated with significant clinical and nonclinical complications. At present, the patent protection of pegfilgrastim (Neulasta®) has expired, and a biosimilar (Ziextenzo®) has been approved. Since the biosimilar price is expected to be lower as compared with the originator’s, the present Drug Budget Impact analysis tries to evaluate whether and how much profitable the biosimilar availability will be for the Italian NHS, in terms of cost containment (savings).Methods and Results: The model time horizon extends to five years. The initial overall number of treatments with pegfilgrastim is estimated based on the number of pegfilgrastim packages (assuming a recommended dose of 6 mg is administered after each cytotoxic chemotherapy) and kept constant in time. The model assumes that, year by year, the number of treatments with the originator will partly switch to the biosimilar (according to an uptake rate assumed). The results show that the availability of the biosimilar would provide an €6.4 million cumulated savings to the NHS in the five years.Conclusions: According to the present analysis, the availability of the biosimilar would generate cumulated savings (in five years) as high as €6.4 million for the Italian NHS. (HTA & Market Access)

show abstract

Section: Discussioneunclassified

Budget impact analysis of pegfilgrastim biosimilar in the treatment of febrile neutropenia in Italy

Ravasio¹,

Antonuzzo

Danova³

et al. 2020

abtpn

View full text Add to dashboard Cite

show abstract

“…Similar models have been previously applied in many studies and searches in the field of health economics evaluation [13][14][15][16][17][18][19][20][21][22] to represent a 1-year static estimation of the economic burden due to disease.…”

Section: Methodsmentioning

confidence: 99%

“…The review allowed systematising the available information, but this may not be representative of the real practice on a national level. To fill this gap, the Open Access model proposed a well-validated probabilistic estimate method, [13][14][15][16][17][18][19][20][21][22] considering the variability in the literature as minimum and maximum range in which it was highly possible to obtain the real inference estimate.…”

Section: Statistical Analysesmentioning

confidence: 99%

Economic Burden of Schizophrenia in Italy: A Probabilistic Cost of Illness Analysis

et al. 2016

View full text Add to dashboard Cite

Objectives Schizophrenia is a chronic, debilitating psychiatric disease with highly variable treatment pathways and consequent economic impacts on resource utilisation. The aim of the study was to estimate the economic burden of schizophrenia in Italy for both the societal and Italian National Healthcare perspective. Methods A probabilistic cost of illness model was applied. A systematic literature review was carried out to identify epidemiological and economic data. Direct costs were calculated in terms of drugs, hospitalisations, specialist services, residential and semiresidential facilities. Indirect costs were calculated on the basis of patients' and caregivers' loss of productivity. In addition, the impact of disability compensation was taken into account using a database from the Italian National Social Security Institute -Italy (INPS). results Overall, 303 913 prevalent patients with schizophrenia were estimated. Of these, 212 739 (70%) were diagnosed and 175 382 (82%) were treated with antipsychotics. The total economic burden was estimated at €2.7 billion (95% CI €1771.93 to €3988.65), 50.5% due to indirect costs and 49.5% to direct costs. Drugs corresponded to 10% of direct costs and hospitalisations (including residential and semiresidential facilities) accounted for 81%. Conclusions This study highlighted that indirect costs and hospitalisations (including residential and semiresidential facilities) play a major role within the expenses associated with schizophrenia in Italy, and this may be considered as a tool for public decision-makers.

show abstract

“…Complessivamente, in Italia, sono stati stimati circa 267.190 soggetti (IC95%: 161.093-494.451) con diagnosi di HCV con livello di fibrosi da F0 a F4 (5), i quali rappresentano la radice epidemiologica dell'analisi. Tuttavia, rispecchiando la pratica clinica corrente, il modello assume che i pazienti in trattamento farmacologico siano i soli pazienti con grado F3-F4.…”

Section: Scenari DI Analisiunclassified

“…Tuttavia, rispecchiando la pratica clinica corrente, il modello assume che i pazienti in trattamento farmacologico siano i soli pazienti con grado F3-F4. Viceversa, i pazienti negli stati F0-F2 vengono seguiti dai centri clinici e rappresentano il solo serbatoio di pazienti che nel corso degli anni peggioreranno il loro stato di fibrosi e verranno trattati una volta che avranno raggiunto i livelli di fibrosi previsti per l'inizio del trattamento (5).…”

Section: Scenari DI Analisiunclassified

Willingness to pay for innovation: the case of the anti-HCV drugs from the Italian National Health Service perspective

Mennini

Marcellusi

Viti

et al. 2015

Global & Regional Health Technology Assessment

View full text Add to dashboard Cite

ORIGINAL ARTICLE getti con una positività ematica all'HCV RNA è generalmente superiore al 3% nei nati prima del 1950 e aumenta progressivamente con l'età, mentre è considerevolmente più bassa, in assenza di tossicodipendenza, nelle generazioni più giovani (1). Il problema dell'infezione da HCV risiede nella possibile evoluzione clinica che si manifesta nel soggetto infetto nel medio/lungo periodo. Nel corso degli anni, infatti, l'HCV cronica può portare alla cirrosi epatica e, infine, alla morte. L'HCV è una malattia asintomatica e, come tale, viene trattata principalmente in una fase avanzata (1). Tra i pazienti che acquisiscono l'infezione da HCV, infatti, oltre il 90% diventa portatore cronico, sviluppando nel 65-95% dei casi un'epatopatia cronica e nel 10-30% dei casi un rischio di evolvere in cirrosi nell'arco di 25-30 anni (2). I soggetti cirrotici a loro volta hanno una probabilità per anno dell'1-3% di sviluppare

show abstract

Costi diretti e indiretti assorbiti dalle patologie HCV-indotte in Italia: stima basata su una metodologia probabilistica di Cost of Illness

Cited by 14 publications

References 24 publications

Budget impact analysis of pegfilgrastim biosimilar in the treatment of febrile neutropenia in Italy

Budget impact analysis of pegfilgrastim biosimilar in the treatment of febrile neutropenia in Italy

Economic Burden of Schizophrenia in Italy: A Probabilistic Cost of Illness Analysis

Willingness to pay for innovation: the case of the anti-HCV drugs from the Italian National Health Service perspective

Contact Info

Product

Resources

About